Skip to content

Study · Not a test of the peptide alone · 2004

2 results

Dual secretagogue drive of burst-like growth hormone secretion in postmenopausal compared with premenopausal women studied under an experimental estradiol clamp.

Erickson D, Keenan DM, Mielke K, Bradford K, Bowers CY, Miles JM, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 Sept 2004Cited by 21 (Europe PMC)

PMID15356089 (opens in a new tab)DOI10.1210/jc.2004-0424 (opens in a new tab)PepBankPUB-15356089
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneObservational studyMechanism

    Under an estradiol clamp, postmenopausal women had lower GH secretion than premenopausal women after paired secretagogues, including l-arginine with GHRP‑2 and GHRP‑2 with GHRH.

    In plain wordsIn women under a set estradiol level, growth hormone release after paired stimulation tests, including GHRP‑2 pairs, was lower after menopause than before.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH secretion after paired secretagogue stimulation including GHRP-2
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    3) attenuated GH secretion after maximal stimulation by the paired secretagogues l-arginine/GH-releasing peptide (GHRP)-2, l-arginine/GHRH, and GHRP-2/GHRH

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneObservational studyMechanism

    Under an estradiol clamp, menopausal status did not determine peptide-induced GH waveform shortening.

    In plain wordsIn women under a set estradiol level, menopause did not change how the stimulating peptides shortened the growth hormone waveform.

    Peptide
    GHRP-2
    Outcome
    No significant changePeptide-induced GH waveform shortening by menopausal status
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    peptide-induced waveform shortening.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.